Status:
UNKNOWN
162 mg of Aspirin for Prevention of Preeclampsia
Lead Sponsor:
Methodist Medical Center of Illinois
Collaborating Sponsors:
University of Illinois College of Medicine at Peoria
UICOM Peoria Family Medicine Residency
Conditions:
Preeclampsia
Eligibility:
FEMALE
Phase:
PHASE4
Brief Summary
This is a study to assess if 162 mg of aspirin will decrease rates of preeclampsia in pregnant patients compared to 81 mg of aspirin.
Detailed Description
After screening to meet inclusion criteria, pregnant patients at the Family Medicine Clinic will be asked to take 162 mg aspirin daily for 6 months, starting at about 12 weeks gestation and continued ...
Eligibility Criteria
Inclusion
- Any pregnant patient at Peoria FMC
- Hx of pre-eclampsia
- Multifetal gestation
- Chronic hypertension
- Type 1 or 2 diabetes
- Autoimmune disease
- Renal disease
- Nulliparity
- Obesity
- Family Hx of pre-eclampsia
- Sociodemographic characteristics
- Age \>= 35 years of age
- Personal history factors (LBW, SGA, \> 10-year pregnancy interval, adverse pregnancy outcomes
Exclusion
- At high risk of side effects from ASA therapy
- Hx of hemorrhagic stroke
- Hx of GI bleed, G6PD
- Liver disease
- NSAID or Salicylate allergy)
- Patients confirmed to be not compliant with therapy
Key Trial Info
Start Date :
July 6 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 9 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05221164
Start Date
July 6 2021
End Date
June 9 2022
Last Update
February 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UnityPoint Clinic Family Medicine
Peoria, Illinois, United States, 61602